New AI tool could spot hidden prostate cancer on MRI scans

NCT ID NCT05710380

Recruiting now Diagnosis Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new software tool that automatically analyzes MRI images of the prostate to find cancer areas that doctors might miss. About 180 people with known or suspected prostate cancer will get an MRI and then a targeted biopsy. Researchers will compare the software's accuracy to that of experienced radiologists. The goal is to see if the tool can improve diagnosis and reduce missed cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Risk Map Decision Support System (DSS) software
What this could lead to: If successful, this software could help doctors find prostate cancer more accurately during MRI scans, reducing missed cancers and unnecessary biopsies.
What could go wrong: This is an early-stage study with only 180 participants, so the software may not prove more accurate than current methods. It is a diagnostic tool, not a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA PROSTATE CANCER PROSTATE NEOPLASM

Contacts and locations

Locations

University of Chicago Medicine Comprehensive Cancer Center
RECRUITING

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.